Results 201 to 210 of about 148,501 (250)

Identification of a presymptomatic and early disease signature for Amyotrophic Lateral Sclerosis (ALS): protocol of the premodiALS study

Tzeplaeff L, Galhoz A, Meijs C, Caldi Gomes L, Kovac A, Menzel A, Değirmenci H, Alaamel A, Can Kaya H, Günalp Çelik A, Dinçer S, Korucuk M, Berker Karaüzüm S, Bayraktar E, Çiftçi V, Bilge U, Koç F, Demleitner AF, Buchberger A, von Heynitz R, Gmeiner V, Knellwolf C, Mouzouri M, Wuu J, Başak AN, Munch Andersen P, Kohlmayer F, Ashton NJ, Kuban W, Lenz C, Rogers M, Zilka N, Corcia P, Lerner Y, Weber M, Turcanova Koprusakova M, Uysal H, Benatar M, Menden MP, Lingor P.   +39 more
europepmc   +1 more source

Trimetazidine, a promising drug for amyotrophic lateral sclerosis, modulates Ca2+ influx in spinal neurons

Bernardi S, Vitolo S, Gabellini C, Marchese M, Ferraro E.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Amyotrophic lateral sclerosis.

Current Opinion in Neurology, 2012
PURPOSE OF REVIEW The field of amyotrophic lateral sclerosis (ALS) has seen a number of remarkable advances during recent years that will be summarized in this review. RECENT FINDINGS In particular, the progress in the molecular neuropathology with the
A. Ludolph, J. Brettschneider, Jochen H Weishaupt   +2 more
semanticscholar   +3 more sources

Amyotrophic lateral sclerosis

The Lancet, 2007
Amyotrophic lateral sclerosis (known in the UK as motor neuron disease) is a devastating illness with uncertain pathogenesis. In this Seminar, we review its natural history, clinical features, diagnostic criteria, variant and mimic syndromes, genetic forms, and epidemiology.
J D, Mitchell, G D, Borasio
openaire   +3 more sources

Amyotrophic Lateral Sclerosis

Seminars in Neurology, 2014
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting 20,000 to 30,000 people in the United States. The mainstay of care of patients affected by this disease is supportive and given the multifaceted nature of their needs is provided most efficiently through multidisciplinary clinics that have shown to prolong ...
Rabia, Malik, Andrew, Lui, Catherine, Lomen-Hoerth   +2 more
openaire   +3 more sources

Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis

Annals of Neurology, 2021
The diagnosis of amyotrophic lateral sclerosis (ALS) remains problematic, with current diagnostic criteria (revised El Escorial [rEEC] and Awaji) being complex and prone to error.
Andrew P Hannaford, Nathan Pavey, M. V. D. van den Bos, N. Geevasinga, P. Menon, J. Shefner, M. Kiernan, S. Vucic   +7 more
semanticscholar   +1 more source

Amyotrophic Lateral Sclerosis

Science of Aging Knowledge Environment, 2003
In this case study, we describe the symptoms, neurological examination, and pathology of a woman with amyotrophic lateral sclerosis (ALS). ALS is a rare disorder leading to degeneration of the voluntary motor system and death in, on average, 3 to 4 years. The loss of motor neurons in the brain and spinal cord causes the progressive symptoms of muscular
Paul H, Gordon, Hiroshi, Mitsumoto, Arthur P, Hays   +2 more
openaire   +2 more sources

Amyotrophic lateral sclerosis

Current Opinion in Neurology, 1980
Therapeutic trials for amyotrophic lateral sclerosis have attracted much attention, but no drug tested has been effective yet. Three major theories of pathogenesis form the basis for these trials: autoimmunity, chronic excitotoxic stimulation due to accumulation of glutamate, and, in the familial form, peroxidation due to subnormal activity of ...
openaire   +2 more sources

Amyotrophic lateral sclerosis

2023
The scientific landscape surrounding amyotrophic lateral sclerosis has shifted immensely with a number of well-defined ALS disease-causing genes, each with related phenotypical and cellular motor neuron processes that have come to light. Yet in spite of decades of research and clinical investigation, there is still no etiology for sporadic amyotrophic ...
David S, Younger, Robert H, Brown
openaire   +2 more sources

Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis

European Journal of Neurology, 2020
The prognostic value of serum neurofilament light chain (sNfL), a biomarker of neurodegeneration, compared to other prognostic factors of amyotrophic lateral sclerosis (ALS) at the time of diagnosis, remains unclear.
E. Thouvenot, C. Demattei, S. Lehmann, A. Maceski‐Maleska, C. Hirtz, R. Juntas-Morales, N. Pageot, F. Esselin, S. Alphandéry, T. Vincent, W. Camu   +10 more
semanticscholar   +1 more source